GlobeNewswire Inc.··Pomerantz LlpORIC Pharma Plummets 41% as Cancer Drug Fails to Deliver Best-in-Class Promise
Pomerantz Law Firm investigates securities fraud claims against $ORIC after 41% stock crash following disappointing prostate cancer treatment results.
ORICsecurities fraudclass action lawsuit